Home
Company
Back
Company
Team
Corporate deck
History
Investors
CCS1477
Back
CCS1477
Publications
Collaborations
Differentiation
Clinical
Back
Clinical
Prostate Cancer
Haematology
Targeted Tumours
News
Back
News
Press releases
Blogs
Contact
Blogs
Short information articles
on our science and its application
Jan 14, 2021
CCS1477 publishes in Cancer Discovery: a new strategy to treat cancer
Oct 27, 2020
Patient focused pull; pioneering research push
Aug 6, 2020
Flexible, expedient management of our clinical trials
Apr 16, 2020
Targeting p300/CBP through to specific oncology applications
Feb 20, 2020
The discovery of CCS1477, first of its kind, p300/CBP inhibitor
Jan 15, 2020
Targeting p300/CBP: a new approach to treating cancer
More press releases
Applications of CCS1477
Prostate Cancer
Late stage, metastatic castrate-resistant prostate cancer (mCRPC)
Haematology
Blood cancers including multiple myeloma, AML and lymphomas
Targeted Tumours
Tumours with p300 or CBP mutations, or driven by AR or MYC